Green Health & Wellness Novo Nordisk says experimental drug amycretin show 13% weight loss in trial – GWC Mag gwcmagMarch 14, 2024027 views Business & FinanceHealth 07 March 2024, 2:04 pm 1 minute Reuters was first to report on the early trial data for Novo Nordisk’s highly anticipated experimental drug amycretin which showed that participants had a weight loss of 13.1% after 12 weeks, prompting the company’s shares to rise to record highs and placing it above Tesla by market valuation. Market Impact Shares surged more than 8% to record highs, shooting Novo Nordisk up in global rankings to the 12th most valuable company from 14 previously. Article Tags Topics of Interest: Business & FinanceHealth Type: Reuters Best Sectors: Business & FinancePharmaceuticals & Healthcare Regions: Americas Countries: United States Win Types: Speed Story Types: Exclusive / Scoop Media Types: Text Customer Impact: Significant National Story